Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phillip G Febbo

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Nature Cell Biology|June 13, 2024
Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progressionMeng Zhang, Martin Sjöström, Xiekui Cui, et al.
Cancer Cell|June 28, 2002
Gene expression correlates of clinical prostate cancer behaviorDinesh Singh, Phillip G Febbo, Kenneth Ross, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 28, 2009
The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft modelJohn C Mavropoulos, W Cooper Buschemeyer, Alok K Tewari, et al.
The Journal of Urology|March 11, 2018
A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate BiopsyAmirali Salmasi, Jonathan Said, Alan W Shindel, et al.
Urology|January 3, 2016
Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate ScoreTimothy C Brand, Nan Zhang, Michael R Crager, et al.
European Urology Oncology|May 11, 2025
Prevalence of Potential Candidates for Targeted Therapies According to Treatment-related Transcriptomic Signatures Among 140 548 Patients with Nonmetastatic Prostate CancerNicole Handa, Eric V Li, Jamie Michael, et al.
The EMBO Journal|January 7, 2005
Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative diseaseJing Wang, Hiromi Iwasaki, Andrei Krivtsov, et al.
Journal of the National Cancer Institute|March 26, 2009
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancerToshiro Migita, Stacey Ruiz, Alessandro Fornari, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2008
NCCN Task Force Report: mTOR inhibition in solid tumorsRobert A Figlin, Elizabeth Brown, Andrew J Armstrong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancerAndrew J Armstrong, George J Netto, Michelle A Rudek, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Nature Cell Biology|June 13, 2024
Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progressionMeng Zhang, Martin Sjöström, Xiekui Cui, et al.
Cancer Cell|June 28, 2002
Gene expression correlates of clinical prostate cancer behaviorDinesh Singh, Phillip G Febbo, Kenneth Ross, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 28, 2009
The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft modelJohn C Mavropoulos, W Cooper Buschemeyer, Alok K Tewari, et al.
The Journal of Urology|March 11, 2018
A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate BiopsyAmirali Salmasi, Jonathan Said, Alan W Shindel, et al.
Urology|January 3, 2016
Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate ScoreTimothy C Brand, Nan Zhang, Michael R Crager, et al.
European Urology Oncology|May 11, 2025
Prevalence of Potential Candidates for Targeted Therapies According to Treatment-related Transcriptomic Signatures Among 140 548 Patients with Nonmetastatic Prostate CancerNicole Handa, Eric V Li, Jamie Michael, et al.
The EMBO Journal|January 7, 2005
Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative diseaseJing Wang, Hiromi Iwasaki, Andrei Krivtsov, et al.
Journal of the National Cancer Institute|March 26, 2009
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancerToshiro Migita, Stacey Ruiz, Alessandro Fornari, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2008
NCCN Task Force Report: mTOR inhibition in solid tumorsRobert A Figlin, Elizabeth Brown, Andrew J Armstrong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancerAndrew J Armstrong, George J Netto, Michelle A Rudek, et al.
Pageof 8